Eli Lilly Net Profit Margin 1986-2025 | LLY

Current and historical net profit margin for Eli Lilly (LLY) from 1986 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue. Eli Lilly net profit margin for the three months ending June 30, 2025 was .
Eli Lilly Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2025-06-30 $53.26B $13.80B 25.91%
2025-03-31 $49.00B $11.11B 22.66%
2024-12-31 $45.04B $10.59B 23.51%
2024-09-30 $40.86B $8.37B 20.48%
2024-06-30 $38.92B $7.34B 18.87%
2024-03-31 $35.93B $6.14B 17.09%
2023-12-31 $34.12B $5.24B 15.36%
2023-09-30 $32.07B $4.99B 15.56%
2023-06-30 $29.52B $6.50B 22.02%
2023-03-31 $27.69B $5.69B 20.54%
2022-12-31 $28.54B $6.25B 21.88%
2022-09-30 $29.24B $6.03B 20.64%
2022-06-30 $29.07B $5.69B 19.58%
2022-03-31 $29.32B $6.13B 20.90%
2021-12-31 $28.32B $5.58B 19.71%
2021-09-30 $27.76B $5.97B 21.51%
2021-06-30 $26.73B $6.07B 22.71%
2021-03-31 $25.49B $6.09B 23.90%
2020-12-31 $24.54B $6.19B 25.24%
2020-09-30 $23.21B $5.57B 24.01%
2020-06-30 $22.95B $5.62B 24.48%
2020-03-31 $23.09B $5.53B 23.97%
2019-12-31 $22.32B $8.32B 37.27%
2019-09-30 $21.84B $7.95B 36.39%
2019-06-30 $21.67B $7.84B 36.19%
2019-03-31 $21.62B $6.26B 28.94%
2018-12-31 $21.49B $3.23B 15.04%
2018-09-30 $19.12B $0.45B 2.35%
2018-06-30 $19.47B $-0.14B -0.74%
2018-03-31 $19.71B $1.12B 5.70%
2017-12-31 $19.97B $-0.20B -1.02%
2017-09-30 $22.47B $2.23B 9.90%
2017-06-30 $22.01B $2.45B 11.12%
2017-03-31 $21.59B $2.19B 10.13%
2016-12-31 $21.22B $2.74B 12.90%
2016-09-30 $20.84B $2.44B 11.73%
2016-06-30 $20.61B $2.47B 11.97%
2016-03-31 $20.18B $2.32B 11.49%
2015-12-31 $19.96B $2.41B 12.07%
2015-09-30 $19.71B $2.36B 11.98%
2015-06-30 $19.62B $2.06B 10.50%
2015-03-31 $19.58B $2.19B 11.21%
2014-12-31 $19.62B $2.39B 12.19%
2014-09-30 $20.30B $2.69B 13.25%
2014-06-30 $21.20B $3.39B 16.00%
2014-03-31 $22.20B $3.86B 17.41%
2013-12-31 $23.11B $4.68B 20.26%
2013-09-30 $23.26B $4.78B 20.57%
2013-06-30 $22.93B $4.91B 21.40%
2013-03-31 $22.60B $4.63B 20.47%
2012-12-31 $22.60B $4.09B 18.09%
2012-09-30 $22.69B $4.12B 18.16%
2012-06-30 $23.40B $4.03B 17.22%
2012-03-31 $24.05B $4.30B 17.89%
2011-12-31 $24.29B $4.35B 17.90%
2011-09-30 $24.43B $4.66B 19.07%
2011-06-30 $23.93B $4.73B 19.75%
2011-03-31 $23.43B $4.88B 20.82%
2010-12-31 $23.08B $5.07B 21.97%
2010-09-30 $22.82B $4.82B 21.10%
2010-06-30 $22.73B $4.45B 19.59%
2010-03-31 $22.28B $4.26B 19.14%
2009-12-31 $21.84B $4.33B 19.83%
2009-09-30 $21.11B $-0.22B -1.02%
2009-06-30 $20.75B $-1.62B -7.82%
2009-03-31 $20.61B $-1.82B -8.84%
2008-12-31 $20.37B $-2.07B -10.17%
2008-09-30 $20.36B $2.41B 11.84%
2008-06-30 $19.74B $3.80B 19.27%
2008-03-31 $19.22B $3.51B 18.26%
2007-12-31 $18.63B $2.95B 15.85%
2007-09-30 $17.69B $2.23B 12.61%
2007-06-30 $16.97B $2.18B 12.84%
2007-03-31 $16.20B $2.34B 14.42%
2006-12-31 $15.69B $2.66B 16.97%
2006-09-30 $15.33B $3.23B 21.09%
2006-06-30 $15.06B $3.15B 20.93%
2006-03-31 $14.86B $2.08B 13.98%
2005-12-31 $14.65B $1.98B 13.52%
2005-09-30 $14.41B $1.28B 8.86%
2005-06-30 $14.09B $1.24B 8.79%
2005-03-31 $13.98B $2.15B 15.36%
2004-12-31 $13.86B $1.81B 13.06%
2004-09-30 $13.68B $2.56B 18.71%
2004-06-30 $13.54B $2.52B 18.60%
2004-03-31 $13.07B $2.55B 19.53%
2003-12-31 $12.58B $2.56B 20.35%
2003-09-30 $12.07B $2.55B 21.11%
2003-06-30 $11.72B $2.52B 21.50%
2003-03-31 $11.41B $2.49B 21.80%
2002-12-31 $11.08B $2.71B 24.44%
2002-09-30 $10.95B $2.55B 23.26%
2002-06-30 $11.04B $2.43B 22.04%
2002-03-31 $11.30B $2.60B 23.03%
2001-12-31 $11.54B $2.78B 24.08%
2001-09-30 $11.69B $2.97B 25.42%
2001-06-30 $11.63B $3.18B 27.35%
2001-03-31 $11.22B $3.02B 26.91%
2000-12-31 $10.86B $3.06B 28.15%
2000-09-30 $10.71B $3.08B 28.74%
2000-06-30 $10.48B $3.03B 28.92%
2000-03-31 $10.20B $2.94B 28.84%
1999-12-31 $10.00B $2.72B 27.20%
1999-09-30 $9.82B $2.50B 25.48%
1999-06-30 $9.81B $2.29B 23.32%
1999-03-31 $9.81B $2.20B 22.46%
1998-12-31 $9.82B $2.10B 21.36%
1998-09-30 $9.44B $1.99B 21.06%
1998-06-30 $9.03B $1.93B 21.34%
1998-03-31 $8.69B $-0.30B -3.41%
1997-12-31 $8.37B $-0.38B -4.59%
1997-09-30 $8.17B $-0.47B -5.74%
1997-06-30 $7.82B $-0.51B -6.52%
1997-03-31 $7.52B $1.57B 20.86%
1996-12-31 $7.35B $1.52B 20.75%
1996-09-30 $7.09B $1.49B 21.09%
1996-06-30 $6.91B $2.31B 33.36%
1996-03-31 $6.83B $2.29B 33.48%
1995-12-31 $6.76B $2.29B 33.87%
1995-09-30 $6.51B $2.24B 34.37%
1995-06-30 $6.39B $1.33B 20.81%
1995-03-31 $6.45B $1.35B 20.91%
1994-12-31 $6.04B $1.29B 21.30%
1994-09-30 $6.30B $0.47B 7.51%
1994-06-30 $6.32B $0.45B 7.09%
1994-03-31 $6.20B $0.45B 7.22%
1993-12-31 $6.45B $0.48B 7.44%
1993-09-30 $6.31B $1.32B 20.85%
1993-06-30 $6.25B $0.75B 12.03%
1993-03-31 $6.17B $0.75B 12.07%
1992-12-31 $6.17B $0.71B 11.48%
1992-09-30 $6.09B $0.71B 11.64%
1992-06-30 $5.95B $1.28B 21.43%
1992-03-31 $5.85B $1.25B 21.43%
1991-12-31 $5.73B $1.32B 22.98%
1991-09-30 $5.60B $1.26B 22.51%
1991-06-30 $5.54B $1.22B 22.01%
1991-03-31 $5.39B $1.18B 21.81%
1990-12-31 $5.19B $1.13B 21.71%
1990-09-30 $4.53B $1.10B 24.21%
1990-06-30 $4.30B $1.05B 24.49%
1990-03-31 $4.19B $1.00B 23.74%
1989-12-31 $4.18B $0.94B 22.49%
1989-09-30 $3.97B $0.89B 22.41%
1989-06-30 $3.87B $0.85B 21.95%
1989-03-31 $3.76B $0.81B 21.62%
1988-12-31 $3.61B $0.76B 21.09%
1988-09-30 $3.64B $0.72B 19.87%
1988-06-30 $3.66B $0.70B 19.21%
1988-03-31 $3.66B $0.67B 18.34%
1987-12-31 $3.65B $0.64B 17.64%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $495.141B $28.541B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12